RE: A big thank you on biosafety

I Agree when in doubt pass it by the Institutional Biosafety Committee.

However, according to Paul Brown, MD and Christian Abee, DVM
''Historically, all TSE agents have been considered to require handling
according to modified BSL-2 conditions. The principal differences between
BSL-2 and -3 regulations concern the risk posed by aerosol infections, and
the stringency of disposal of contaminated materials. BSL-2 conditions
assume that aerosol infections do not occur, and that contaminated
materials are comparatively easy to disinfect; BSL-3 conditions assume that
aerosol infections do occur, and that contaminated materials are difficult
to disinfect. Because TSE agents are not spread by aerosol but are
extremely difficult to disinfect, BSL-2 conditions have been modified to
include the use of laminar flow hoods to facilitate containment of the
infectious agents''.

http://dels.nas.edu/ilar_n/ilarjournal/46_1/html/v4601brown.shtml  (2005)

BSE and  vCJD should be worked on under BSL3 containment.  All other TSEs
are subject to modified BSL-2 requirements that may vary from state to
state and situation to situation. For example, procedures that involve
direct contact/manipulation of human tissue or a human TSE passaged through
a nonhuman primate may require a BSL-3 facility, whereas tissue storage or
housing of animals inoculated with these TSEs are satisfied by BSL-2
conditions (Richmond and McKinney 1999).

Richmond JY, McKinney R, eds. 1999. Biosafety in Microbiological and
Biomedical Laboratories. 4th ed. Washington DC: GPO.

Cheers

Erling

**************************************************************
Dr Erling W Rud, PhD
Senior Scientific Advisor
Health Canada,
Health Products and Food Branch,
Food Directorate,
Animal Resources Division,
Sir Frederick G. Banting Research Centre,
Building 22, Room C308, PL 2203E,
251 Sir Frederick Banting Driveway
Ottawa, Ontario, Canada. K1A 0L2

Tel (613) 957-8049
Fax (613) 941-6625
email: erling_rud@hc-sc.gc.ca (Health Canada email)


		      "Joern Schmitz"							  		      <jschmitz@bidmc.h        To:	 Cytometry Mailing List
<cytometry@flowcyt.cyto.purdue.edu>				  
		      arvard.edu>	       cc:					  					       Subject:  RE: A big thank you on biosafety 		      2006-09-08 05:05							  		      PM								  


I totally agree: The Institutional Biosafety Committee has to look at this.

BTW: Who has decided that the biosafety level should "only" be BSL-2 when
you are handling "bugs" that are basically indestructible?

My gut feeling tells me that right now nobody really has any clue about any
potential longterm effects of aerosols from these specimens that you are
about to generate ...

Joern E. Schmitz, MD
Assistant Professor of Medicine
Harvard Medical School
Division of Viral Pathogenesis
Department of Medicine
Beth Israel Deaconess Medical Center
Research East 213D
41 Avenue Louis Pasteur
Boston, MA  02115
Phone: 617-667-5206
Fax:   617-667-8210
http://bidmc.harvard.edu/display.asp?leaf_id=4102
http://www.hms.harvard.edu/aids/programs/cfar/cores/immflowlma.htm
This document may contain information that is privileged, CONFIDENTIAL and
exempt from disclosure under applicable law. If you are not the intended
recipient, please notify me immediately, as the use of this information is
strictly prohibited.
-----Original Message-----
From: Charles A Kuszynski [mailto:ckuszyns@UNMC.EDU]
Sent: Thursday, September 07, 2006 11:22 AM
To: cyto-inbox
Subject: Re: A big thank you on biosafety

I would be more concerned about the potential for aerosol production and
biosafety issues than whether you can clean the sample tube.  Your
institutional Biosafety Committee needs to look at this project and suggest
the requirements for operator safety and containment.

Charles A. Kuszynski, Ph.D.
Assistant Professor
Director, Cell Analysis Facility
University of Nebraska Medical Center
985816 Nebraska Medical Center
Omaha, NE 68198-5816
402 559-6299 office
402 559-6267 lab
402 980-7654 cell
402 559-4069 fax
ckuszyns@unmc.edu

***The University of Nebraska Medical Center E-mail Confidentiality
Disclaimer***
The information in this email is privileged and confidential, intended only
for the use of the addresse(s) above.  Any unauthorized use or disclosure
of this information is prohibited.  If you have received this email by
mistake, please delete it and immediately contact the sender.


      Anne C Avery
      <Anne.Avery@ColoS
      tate.EDU> 				      To
	   Cytometry Mailing List
      09/05/2006 03:15	       <cytometry@flowcyt.cyto.purdue.edu>
      PM					cc
	   Subject
	   Re: A big thank you on biosafety




Hello,

An investigator here has inquired about using the MoFlo for sorting
prion infected material.  This will be from deer and elk with chronic
wasting disease, which is treated as BSL2, and may eventually also be
scrapie, which I think is also BSL2.

I was wondering if anyone out there has done these kinds of sorts, and
if so, what sort of containment and line decontamination they have used?

Thanks very much.

Anne

--
Anne Avery, VMD, PHD
College of Veterinary Medicine and Biomedical Sciences
Department of Microbiology, Immunology and Pathology
1619 Campus Delivery
Fort Collins, Colorado	       80523-1619
voice:(970)491-1170
fax:(970)491-0603
anne.avery@colostate.edu